Adenosine A2A receptor pathway
This page describes a pathway reported in the literature. It is not a claim about any product and does not recommend any procedure.
Mechanisms
What is PDRN and what is its mechanism of action?
PDRN is a mixture of DNA-derived polymer fragments, described in the literature with molecular weights between roughly 50 and 1,500 kDa. Its reported mechanism runs through engagement of the adenosine A2A receptor, together with salvage-pathway activity that supplies nucleotides for cell metabolism. Reviews describe anti-inflammatory, anti-ischaemic and tissue-repair activity following from this. The same receptor axis is not uniformly favourable: in scleroderma research, inhibiting adenosine and A2A signalling is reported to suppress dermal fibrosis.
Reported sequence
| Step | What the literature reports | Basis |
|---|---|---|
| Fragment mixture | PDRN is not a single molecule. It is a mixture of deoxyribonucleotides obtained by controlled purification, with molecular weights reported between roughly 50 and 1,500 kDa. | PMID 28491036 |
| A2A receptor engagement | The reported mechanism runs through agonism at the adenosine A2A receptor, which is where the anti-inflammatory and anti-ischaemic activity in the literature is attributed. | PMID 28491036 |
| Salvage pathway | The nucleotide fragments are described as feeding the salvage pathway, supplying material for cell metabolism without de novo synthesis. | PMID 28491036 |
| Reported tissue effects | Systematic review of wound healing and tissue regeneration collects the reported outcomes attributed to this activity. | PMID 32757710 |
Evidence that reads the other way
Research on systemic sclerosis reports the opposite direction on the same axis: inhibiting adenosine and A2A receptor signalling suppressed dermal fibrosis by enhancing fatty acid oxidation. A receptor pathway cited as pro-repair in one context is described as a fibrosis driver in another. This does not cancel the repair literature — the disease models and endpoints differ — but any account of A2A that presents the axis as uniformly beneficial is incomplete.
Materials where this is cited
Evidence
| PMID | Study type | Summary |
|---|---|---|
| 28491036 | review | Review of PDRN pharmacological activity, describing A2A receptor agonism and salvage-pathway activity — Front Pharmacol, 2017 |
| 40871045 | review | Review comparing polynucleotide and polydeoxyribonucleotide, attributing distinct functions to differences in polymer length and molecular weight — Pharmaceutics, 2025 |
| 32757710 | review | Systematic review of PDRN effects on wound healing and tissue regeneration — Regen Med, 2020 |
| 40301970 | in vivo | Inhibition of adenosine and A2A receptor signalling suppressed dermal fibrosis by enhancing fatty acid oxidation — Cell Commun Signal, 2025 |
A mixture, not a molecule
The first thing that gets lost when this pathway is summarised is that PDRN is a distribution of fragment sizes, not a compound. The reported molecular weight range spans more than an order of magnitude. Review literature separates polynucleotide from polydeoxyribonucleotide on precisely this variable and attributes different functions to each, so a claim carried between the two names is a claim carried across the variable the literature says matters.
Where this sits relative to the particle materials
The polymer biostimulators elsewhere in this atlas are described as working through a foreign-body response — a physical particle provoking a cellular reaction. This pathway is different in kind: a receptor is engaged and a metabolic pathway is supplied. Grouping nucleotide-derived agents with particulate scaffolds because both are injected obscures that the reported mechanisms have almost nothing in common.
Reading the counterpoint properly
The scleroderma finding does not mean the repair literature is wrong. It means the axis is context-dependent, and that “A2A activation is regenerative” is a summary that holds in some models and reverses in others. For a reference page the honest position is to carry both and let the reader see that the pathway is being asked to do different work in different fields.
Limitations & open questions
The evidence cited here is predominantly review-level, so it summarises primary work rather than measuring the pathway directly. Source material and degree of purification differ between products and the literature does not always specify which was used, which matters because the reported function is attributed to fragment length. PDRN and polynucleotide are frequently treated as one material despite the review literature separating them on exactly that variable. No citation here links a receptor-level finding to a measured clinical endpoint in aesthetic use.